# FDA recall D-181-2013

> **Bristol Myers Squibb Manufacturing Company** · Class II · drug recall initiated 2012-11-02.

## Product

ABILIFY (aripiprazole) Tablets, 30 mg, Rx only, Blister Pack of 100 tablets, Otsuka America Pharmaceutical Inc., Bristol-Myers Squibb NDC 59148-011-35

## Reason for recall

CGMP Deviations: A drum of Abilify 30 mg Tablets rejected during the compression stage was not segregated from the other portion of the lot and was inadvertently shipped, packaged and distributed.

## Distribution

LA, TN, CA

## Key facts

- **Recall number:** D-181-2013
- **Recalling firm:** Bristol Myers Squibb Manufacturing Company
- **Classification:** Class II
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2012-11-02
- **Report date:** 2013-03-13
- **Termination date:** 2013-05-02

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Humacao, PR, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-181-2013

## Citation

> AI Analytics. FDA recall D-181-2013. Retrieved 2026-05-25 from https://api.ai-analytics.org/recall/D-181-2013. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*